Compare Sanofi SA (SNY) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while YieldMax TSLA Option Income Strategy ETF trades at $25.65. The key difference: Sanofi SA pays a 5.5% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Sanofi SA is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| SNY | TSLY | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $52.34 | $48.25 |
52-Week Low | $41.33 | $25.07 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TSLY trades at $25.07, down 2.57% over the past day, with a bearish technical outlook from moving averages and oscillators. The ETF maintains a high distribution yield, with weekly dividends averaging around $0.30 per share, though recent news highlights concerns about capped upside relative to Tesla's performance. Key support sits near $25, while resistance is at $26.
The outlook for TSLY is cautious due to its option income strategy limiting capital appreciation. Risks include volatility from Tesla's stock movements and potential erosion of principal from return of capital distributions. Investors seeking high yield may find value, but must weigh the trade-off between income and growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
